Equities analysts expect that Reata Pharmaceuticals, Inc. (NASDAQ:RETA) will report $1.40 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Reata Pharmaceuticals’ earnings, with estimates ranging from $800,000.00 to $2.00 million. Reata Pharmaceuticals reported sales of $3.19 million in the same quarter last year, which would suggest a negative year over year growth rate of 56.1%. The business is scheduled to announce its next quarterly earnings results on Monday, March 7th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full-year sales of $11.97 million for the current fiscal year, with estimates ranging from $11.40 million to $12.56 million. For the next financial year, analysts anticipate that the firm will report sales of $55.75 million, with estimates ranging from $22.05 million to $73.29 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Monday, November 8th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.32) by $0.35. The business had revenue of $7.40 million during the quarter, compared to analysts’ expectations of $2.07 million. Reata Pharmaceuticals had a negative return on equity of 81.91% and a negative net margin of 2,020.49%. The company’s quarterly revenue was up 428.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.94) EPS.
A number of hedge funds have recently modified their holdings of the stock. First Mercantile Trust Co. raised its holdings in Reata Pharmaceuticals by 20.6% during the third quarter. First Mercantile Trust Co. now owns 721 shares of the company’s stock worth $73,000 after purchasing an additional 123 shares during the last quarter. Bank of New York Mellon Corp increased its position in Reata Pharmaceuticals by 5.0% during the third quarter. Bank of New York Mellon Corp now owns 125,168 shares of the company’s stock worth $12,593,000 after buying an additional 5,999 shares in the last quarter. Gyon Technologies Capital Management LP purchased a new position in Reata Pharmaceuticals during the third quarter worth $478,000. BNP Paribas Arbitrage SA increased its position in Reata Pharmaceuticals by 267.8% during the third quarter. BNP Paribas Arbitrage SA now owns 21,959 shares of the company’s stock worth $2,209,000 after buying an additional 15,989 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in Reata Pharmaceuticals by 188.0% during the third quarter. Squarepoint Ops LLC now owns 19,996 shares of the company’s stock worth $2,012,000 after buying an additional 13,052 shares in the last quarter. 74.04% of the stock is owned by hedge funds and other institutional investors.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Recommended Story: What is a price target?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.